Serum Sickness-like Reaction in a Pediatric Patient using Omalizumab for Chronic Spontaneous Urticaria.
Pediatr Allergy Immunol 2018 Feb 14. Epub 2018 Feb 14.
Department of Pediatrics, Division of Pulmonary, Allergy and Sleep Medicine, Indiana University School of Medicine.
Omalizumab has been approved for chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) in children 12 years and older. Two treatment doses of omalizumab are available: 150 mg or 300 mg every 4 weeks. While 150 mg has been shown to be effective, most patients with CIU/CSU require 300 mg every 4 weeks to achieve symptom improvement. Read More